Profil
Mark Versavel is the founder of Vzenium LLC.
He previously worked as the Chief Medical Officer at Cavion, Inc., Alzheon, Inc., and NeuroBo Pharmaceuticals, Inc. In 2023, he held the position of Chief Medical Officer at Eliem Therapeutics, Inc. Dr. Versavel obtained an MBA from the University of Michigan in 2003.
He also earned a doctorate degree from Humboldt-Universität zu Berlin in 2003 and another doctorate degree from the University of Antwerp in 1983.
Postes actifs de Mark Versavel
| Sociétés | Poste | Début |
|---|---|---|
| Vzenium LLC | Founder | - |
Anciens postes connus de Mark Versavel
| Sociétés | Poste | Fin |
|---|---|---|
| ELIEM THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01/10/2023 |
Cavion, Inc.
 Cavion, Inc. Pharmaceuticals: MajorHealth Technology Cavion, Inc. engages in development of pharmaceuticals products. It produces oncology drugs to treat solid tumors that selectively inhibits the t-type calcium channel. The company was founded by Andrew J. Krouse, Lloyd S. Gray, and Timothy L. Macdonald in 2005 and is headquartered in Charlottesville, VA. | Chief Tech/Sci/R&D Officer | - |
| NEUROBO PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | - |
| ALZHEON, INC. | Chief Tech/Sci/R&D Officer | - |
Formation de Mark Versavel
| University of Michigan | Masters Business Admin |
| Humboldt-Universität zu Berlin | Doctorate Degree |
| University of Antwerp | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| ELIEM THERAPEUTICS, INC. | Health Technology |
| NEUROBO PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Cavion, Inc.
Cavion, Inc. Pharmaceuticals: MajorHealth Technology Cavion, Inc. engages in development of pharmaceuticals products. It produces oncology drugs to treat solid tumors that selectively inhibits the t-type calcium channel. The company was founded by Andrew J. Krouse, Lloyd S. Gray, and Timothy L. Macdonald in 2005 and is headquartered in Charlottesville, VA. | Health Technology |
Alzheon, Inc.
 Alzheon, Inc. BiotechnologyHealth Technology Alzheon, Inc. engages in the provision of medical development. It specializes in treatment for brain health, memory, and aging. It offers ALZ-801, an oral small molecule inhibitor of amyloid formation and neurotoxicity with potential to be a therapy for a genetically defined population of patients with or at high risk for Alzheimer's disease and other neurodegenerative disorders. The company was founded by Martin Tolar in June 2013 and is headquartered in Framingham, MA. | Health Technology |
| Vzenium LLC |
